These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 1421176

  • 1. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis.
    Martin U, Sponer G, Strein K.
    Int J Hematol; 1992 Oct; 56(2):143-53. PubMed ID: 1421176
    [Abstract] [Full Text] [Related]

  • 2. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U, Fischer S, Sponer G.
    J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
    [Abstract] [Full Text] [Related]

  • 3. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U, Dörge L, Fischer S.
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [Abstract] [Full Text] [Related]

  • 4. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ, Smith JM, Storer BL, Granett JR, Bugelski PJ.
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
    Martin U, Sponer G, Strein K.
    J Am Coll Cardiol; 1992 Feb; 19(2):433-40. PubMed ID: 1732372
    [Abstract] [Full Text] [Related]

  • 6. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
    [Abstract] [Full Text] [Related]

  • 7. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
    Martin U, Sponer G, König R, Smolarz A, Meyer-Sabellek W, Strein K.
    Blood Coagul Fibrinolysis; 1992 Apr; 3(2):139-47. PubMed ID: 1606285
    [Abstract] [Full Text] [Related]

  • 8. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP.
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [Abstract] [Full Text] [Related]

  • 9. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 10. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 11. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
    Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, Strein K.
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):111-9. PubMed ID: 1719279
    [Abstract] [Full Text] [Related]

  • 12. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ.
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [Abstract] [Full Text] [Related]

  • 13. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA, Anderson RD, MacCord CS, Scott H, Serebruany V, Herzog WR.
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [Abstract] [Full Text] [Related]

  • 14. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 15. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ, Follenfant MJ, Ford AJ.
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [Abstract] [Full Text] [Related]

  • 16. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR.
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [Abstract] [Full Text] [Related]

  • 17. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS.
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA, Abrahamsson TI, Nerme VK, Mattsson CJ.
    Thromb Res; 2005 Sep; 116(6):519-24. PubMed ID: 16181987
    [Abstract] [Full Text] [Related]

  • 19. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP.
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [Abstract] [Full Text] [Related]

  • 20. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
    Rebello SS, Huang J, Saito K, Saucedo JF, Bates ER, Lucchesi BR.
    Eur J Pharmacol; 1999 Jun 25; 374(3):399-410. PubMed ID: 10422784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.